Kalbe Farma Tbk PT (KLBF) - Total Liabilities
Based on the latest financial reports, Kalbe Farma Tbk PT (KLBF) has total liabilities worth Rp7.31 Trillion IDR (≈ $428.57 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Kalbe Farma Tbk PT (KLBF) long-term investment share to see how much of total assets are deployed in long-term investments.
Kalbe Farma Tbk PT - Total Liabilities Trend (2000–2025)
This chart illustrates how Kalbe Farma Tbk PT's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Kalbe Farma Tbk PT (KLBF) total assets.
Kalbe Farma Tbk PT Competitors by Total Liabilities
The table below lists competitors of Kalbe Farma Tbk PT ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Beijing Zhong Ke San Huan High-Tech Co Ltd
SHE:000970
|
China | CN¥2.40 Billion |
|
Grupo Aval Acciones y Valores S.A
F:6GAA
|
Germany | €315.97 Trillion |
|
Uniti Group Inc.
LSE:0LJB
|
UK | $12.82 Billion |
|
Shenzhen Yinghe Technology Co Ltd
SHE:300457
|
China | CN¥9.94 Billion |
|
Spartan Resources Ltd
AU:SPR
|
Australia | AU$124.04 Million |
|
Anhui Heli Co Ltd
SHG:600761
|
China | CN¥9.14 Billion |
|
Torunlar Gayrimenkul Yatirim Ortakligi AS
IS:TRGYO
|
Turkey | TL24.18 Billion |
|
Intralot S.A. Integrated Lottery Systems and Services
AT:INLOT
|
Greece | €1.35 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down Kalbe Farma Tbk PT's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See KLBF equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kalbe Farma Tbk PT's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kalbe Farma Tbk PT (2000–2025)
The table below shows the annual total liabilities of Kalbe Farma Tbk PT from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Rp5.97 Trillion ≈ $349.87 Million |
+23.38% |
| 2024-12-31 | Rp4.84 Trillion ≈ $283.56 Million |
+22.90% |
| 2023-12-31 | Rp3.94 Trillion ≈ $230.72 Million |
-23.45% |
| 2022-12-31 | Rp5.14 Trillion ≈ $301.42 Million |
+16.89% |
| 2021-12-31 | Rp4.40 Trillion ≈ $257.87 Million |
+2.62% |
| 2020-12-31 | Rp4.29 Trillion ≈ $251.27 Million |
+20.48% |
| 2019-12-31 | Rp3.56 Trillion ≈ $208.55 Million |
+24.81% |
| 2018-12-31 | Rp2.85 Trillion ≈ $167.09 Million |
+4.75% |
| 2017-12-31 | Rp2.72 Trillion ≈ $159.51 Million |
-1.45% |
| 2016-12-31 | Rp2.76 Trillion ≈ $161.85 Million |
+0.15% |
| 2015-12-31 | Rp2.76 Trillion ≈ $161.62 Million |
+5.77% |
| 2014-12-31 | Rp2.61 Trillion ≈ $152.79 Million |
-7.37% |
| 2013-12-31 | Rp2.82 Trillion ≈ $164.95 Million |
+37.57% |
| 2012-12-31 | Rp2.05 Trillion ≈ $119.91 Million |
+16.36% |
| 2011-12-31 | Rp1.76 Trillion ≈ $103.05 Million |
+39.51% |
| 2010-12-31 | Rp1.26 Trillion ≈ $73.86 Million |
-25.49% |
| 2009-12-31 | Rp1.69 Trillion ≈ $99.13 Million |
+24.46% |
| 2008-12-31 | Rp1.36 Trillion ≈ $79.65 Million |
+21.20% |
| 2007-12-31 | Rp1.12 Trillion ≈ $65.72 Million |
+3.79% |
| 2006-12-31 | Rp1.08 Trillion ≈ $63.32 Million |
-40.69% |
| 2005-12-31 | Rp1.82 Trillion ≈ $106.76 Million |
+18.51% |
| 2004-12-31 | Rp1.54 Trillion ≈ $90.08 Million |
+7.89% |
| 2003-12-31 | Rp1.42 Trillion ≈ $83.49 Million |
+4.45% |
| 2002-12-31 | Rp1.36 Trillion ≈ $79.93 Million |
-10.92% |
| 2001-12-31 | Rp1.53 Trillion ≈ $89.73 Million |
+5.46% |
| 2000-12-31 | Rp1.45 Trillion ≈ $85.09 Million |
-- |
About Kalbe Farma Tbk PT
PT Kalbe Farma Tbk., together with its subsidiaries, engages in the development, manufacture, and trading of pharmaceutical products in Indonesia. It operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devi… Read more